RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.[1][2] Its route of administration was unspecified.[1]

The drug reached phase 1 clinical trials prior to the discontinuation of its development.[1][2] It was under development by Hoffmann-La Roche.[1][2] RG-7410 was first disclosed by January 2014[3] and a phase 1 trial was reported to have been completed by October 2014.[4]

See also

References

  1. ^ a b c d e f "RG 7410". AdisInsight. 13 October 2015. Retrieved 23 October 2024.
  2. ^ a b c "Delving into the Latest Updates on RG-7410 with Synapse". Synapse. 19 September 2024. Retrieved 23 October 2024.
  3. ^ "Roche 2013 results" (PDF). Roche Group. London. 30 January 2014.
  4. ^ "Pipeline summary" (PDF). Roche Group. Changes to the development pipeline Q3 2014 update
Allikas: http://en.wikipedia.org/wiki/RG-7410
No tags for this post.